Cramer Remix: This stock has engineered the greatest turnaround story of our era

In This Article:

  • CNBC's Jim Cramer reveals how Bausch Health has put together an amazing comeback.

  • The "Mad Money" host also sits down with the CEO of Zebra Technologies.

  • In the lightning round, Cramer gives a bad review to the Netflix of China.

In an uncertain investing environment, CNBC's Jim Cramer likes to highlight "the best of the best" of the "slowdown plays," or stocks that do well in a weaker economy.

So, on Tuesday, the "Mad Money" host profiled the turnaround at Bausch Health Companies BHC-CA , the drugmaker formerly known as Valeant Pharmaceuticals. Under the leadership of Chairman and CEO Joe Papa, Bausch has undergone what Cramer said "may be the greatest turnaround story of this particular era."

Shares of Bausch, which changed its name from Valeant in July 2018, have more than tripled from their April 2017 lows. The company's latest quarterly report handily beat expectations on earnings and revenue, with organic revenue growth in all of its segments.

"How did Papa do it? First, he told us that he was going to start cleaning up the hideous balance sheet," Cramer said. "Second, he explained that Valeant really did have an attractive pipeline of new drugs, they just needed to double down on developing the good ones. Third, he had to … motivate the staff. It was an incredibly dispirited workforce."

The CEO's hard work has already paid off, but according to Cramer, Bausch's stock is "not done" and is "dirt-cheap" at its current price-to-earnings multiple of seven times next year's earnings estimates.

"The bottom line? Joe Papa has orchestrated an amazing comeback at Bausch Health. The results speak for themselves, which is why I believe, in the end, this story has more room to run," the "Mad Money" host said.

Don't give up on FAANG

Cramer is tired of seeing negative Wall Street coverage suffocate the stocks of Apple and FANG, his acronym for Facebook , Amazon , Netflix and Google, now Alphabet .

"Perhaps the most maligned" of them all is Apple, shares of which fell below their 200-day moving average on Tuesday as they dragged on the broader market , Cramer said.

"The stock has been getting shelled lately, down $41 from its highs, and it shows no sign of stabilizing," he said. "I can see how [buying] Apple here might feel like jumping in front of a speeding freight train."

But analysts, who have been peppering the iPhone maker's stock with downgrades , may be overlooking the possibility that Apple anticipated some sales weakness when it reported earnings on Nov. 1, he said.